.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,977,126

« Back to Dashboard

Details for Patent: 5,977,126

Title: Androstenones
Abstract:The present invention relates to methods for preparing and using compounds of formula (I), wherein carbons 1 and 2 are joined by either a single or a double bond; R.sup.1 is hydrogen or methyl; R.sup.2 is hydrogen or methyl; R.sup.3 is (A) wherein X, W, Z, R.sup.4, and R.sup.5, are various groups, and pharmaceutically acceptable solvates thereof and their use in the treatment of androgen responsive and mediated diseases.
Inventor(s): Batchelor; Kenneth William (Durham, NC), Frye; Stephen Vernon (Durham, NC)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Filing Date:May 14, 1998
Application Number:09/079,002
Claims:1. A method of treating an androgen responsive or mediated disease or condition in a mammal suffering from said disease comprising administering to said mammal, an effective amount of a compound of formula (1) ##STR16## wherein carbons 1 and 2 are joined by either a single or a double bond; R.sup.1 is hydrogen or methyl; R.sup.2 is hydrogen or methyl; R.sup.3 is ##STR17## wherein R.sup.4 and R.sup.5 are independently hydrogen, lower alkyl, lower alkoxy, trifluoromethyl, cyano, halogen, phenyl (optionally substituted with one or more halogens), or when R.sup.4 and R.sup.5 are on adjacent carbons, taken together form a fused 5, 6 or 7 member ring optionally containing one or more oxygen or sulfur atoms; W and Z are alkylene groups which taken together with the carbon to which they are attached form a saturated, 3 to 12 member ring system optionally substituted independently with one or more lower alkyl groups or two of said alkyl groups of said 3 to 12 member ring can joined with a (C.sub.1-6) alkylene group to form a bicyclic ring system, and wherein said 3 to 12 member ring can optionally have an oxygen or sulfur atom,; and X is hydrogen or halogen.

2. A method of claim 1 wherein the androgen responsive or mediated disease or condition is benign prostatic hyperplasia, prostate cancer, acne, male pattern baldness, or hirsuitism.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc